Market
Weight-loss drug market share distribution by end of 2026
2
Resolution / Starting Odds
Orforglipron leads • 25%
Injectables lead • 25%
Equal market share • 25%
Other drugs lead • 25%
Market analysis reports and sales data
Story
Eli Lilly Anticipates Approval for Orforglipron Weight-Loss Pill in Early 2026
Jan 13, 2025, 06:07 PM
Eli Lilly & Co. is anticipating regulatory approval for its experimental weight-loss pill, orforglipron, as early as early 2026, according to CEO Dave Ricks. Ricks, speaking at the JPMorgan Healthcare Conference in San Francisco, indicated that data on the pill is expected by mid-2025. He highlighted that the oral form of the drug would be more convenient for patients and easier to manufacture at a large scale compared to the company's current injectable weight-loss drugs, which have faced supply shortages due to production constraints.
View original story
Similar markets
Both gain equally • 25%
Neither gains market share • 25%
Novo Nordisk gains market share • 25%
Eli Lilly gains market share • 25%
Viking Therapeutics • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Other • 25%
Eli Lilly • 33%
Novo Nordisk • 33%
Another competitor • 34%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
Other • 25%
Viking Therapeutics • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Other • 25%
Pfizer • 25%
Less than 10% • 25%
More than 30% • 25%
20% to 30% • 25%
10% to 20% • 25%
Eli Lilly 40-60% • 25%
Eli Lilly > 60% • 25%
Novo Nordisk 40-60% • 25%
Novo Nordisk > 60% • 25%
Other • 25%
Zepbound • 25%
Wegovy • 25%
Saxenda • 25%
More than 50% • 25%
Less than 30% • 25%
40% to 50% • 25%
30% to 40% • 25%
A new drug from another company • 25%
No new major approvals • 25%
Novo Nordisk's semaglutide 7.2 mg • 25%
Eli Lilly's Zepbound • 25%
Roche • 25%
Johnson & Johnson • 25%
Other • 25%
Pfizer • 25%